California-based AI biotechnology company Erasca signed an agreement with big pharma Novartis to license the latter’s melanoma drug naporafenib for mid-stage development.
As per the agreement. Novartis will be paid USD 20 million upfront cash together with USD 80 million in shares at a rate of USD 6.50 per share. In addition to that, Novartis is eligible for USD 80 million upon achieving regulatory milestones, and another USD 200 million upon achieving sales milestones.
Simultaneously, Erasca raised USD 100 million in an underwritten equity offering of 15.4 million common shares at a rate of USD 6.50 per share. The offering is expected to close on or about December 13, 2022, subject to the fulfillment of certain closing conditions.
The proceeds from the offering will be directed toward the company’s R&D efforts, and advance its development programs. It will also be used for working capital and general purposes.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.